Is This the Era of AI Diagnostics?

About

The immune-checkpoint inhibitor market alone was worth $15.5B in 2023. But could new diagnostics help it exceed its $53.5B predicted value in 2025? Here, AI is becoming a powerful tool.

So will all drugs soon come with their own AI diagnostics? Who will fund their creation and distribution? And what is the clinical appetite for such tools — and will patients accept them?

Join pharmaceutical, clinical, and AI experts to discuss the impact of AI diagnostics on industry and patients.

Moderator

Jesse McQuarters, Branded Content Editor at STAT

Speakers

Kunal Chokshi, M.B.A., AVP, Precision Medicine Merck Oncology

Kunal Chokshi is Associate Vice President of Precision Medicine, Global Oncology Marketing at Merck. He has more than 25 years of industry experience across Pharma and Diagnostic companies and has worked on a broad range of precision medicine launches & diagnostic technologies.

Gazala Khan, M.D., Medical Oncology Specialist

Dr. Gazala Khan is an oncologist affiliated with Henry Ford Hospital in Detroit, Michigan. She received her medical degree from Kilpauk Medical College and has been in practice for more than 20 years. She has expertise in lung cancer, small intestine/colorectal cancer and prostate cancer, amongst other conditions.

Meriem Sefta, Ph.D., Chief Diagnostics Officer, Owkin

Meriem Sefta, Ph.D., is the chief diagnostics officer at Owkin. She graduated from École Polytechnique and MIT and completed her Ph.D. in Cancer Biology at the Curie Institute. Before joining Owkin, she worked at AEC Partners as a Research Project Manager and consultant.